Dopamine receptor D1 (DRD1), Dopamine receptor D2 (DRD2), and Dopamine receptor D3 (DRD3) (DRD1, DRD2, DRD3)

Dopamine receptors D1, D2, and D3 are members of the G protein-coupled receptor (GPCR) superfamily that mediate the physiological actions of the neurotransmitter dopamine in the central nervous system and periphery (UniProt P21728, P14416, P35462). The D1 receptor (DRD1) is primarily coupled to Gs proteins, stimulating adenylyl cyclase and increasing intracellular cAMP, whereas the D2 (DRD2) and D3 (DRD3) receptors are coupled to Gi/o proteins, which inhibit adenylyl cyclase and modulate ion channels (StatPearls, Dopamine Receptors). These receptors play essential roles in regulating motor control, reward-seeking behavior, motivation, and cognitive functions such as working memory (NIH, PubMed). Dysregulation of dopaminergic signaling through these receptors is a hallmark of several neuropsychiatric and neurological disorders, including schizophrenia, Parkinson's disease, and substance use disorders. In schizophrenia, overactivity of D2 receptors in the striatum is associated with positive symptoms, making D2/D3 antagonism a primary mechanism for antipsychotic drugs. Conversely, the loss of dopaminergic neurons in Parkinson's disease leads to reduced receptor activation, which is managed using dopamine agonists that target D1, D2, and D3 receptors to restore motor function. Modern drug development also focuses on partial agonists and biased ligands to achieve therapeutic efficacy while minimizing side effects like extrapyramidal symptoms or impulse control disorders.

Other names

D1RD2RD3RDopamine D1 receptorDopamine D2 receptorDopamine D3 receptor

D2/D3 receptor antagonism, D1/D2/D3 receptor agonism, and D2/D3 partial agonism